Predictive markers of tubulin-targeting agents in breast cancer

Shou-Ching Tang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Microtubules are formed by an equal amount of α- and β-tubulins through a dynamic process of polymerization and depolymerization that reaches equilibrium. Tubulin-targeting agents affect the microtubule function to disrupt cell shape, microvesicle transportation, and spindle formation. The use of tubulin-targeting agents, especially the newer agents such as taxanes, has significantly increased the response and even survival in patients with many cancers, including breast cancer. However, not all patients respond to these agents. Also, most patients develop recurrent or progressive disease, especially in the metastatic setting. The use of predictive markers of tubulin-targeting agents is therefore needed to increase the therapeutic ratio in the selected patient population. However, many clinical studies have failed to identify reliable and reproducible clinical or biologic markers that serve this purpose. Of the various markers examined, β-tubulin III and its related proteins, such as tau, seem to predict the response to taxanes in preliminary clinical studies. However, most of these studies are limited by many factors such as small sample size, heterogeneous patient population, disease stages, and different methods in marker detection. None of these markers have been validated by large prospective clinical trials. Since tumor cells are driven by many signal transduction pathways, the study of the gene expression signature rather than a single gene is more likely to identify the ultimate predictive markers of response to tubulin-targeting agents. Gene expression profiling and proteomics are in preclinical development and in early clinical trials. They will eventually enable us to offer patients tailored chemotherapy with the tubulin-targeting agents. Before such predictive markers are available, these agents may be considered in patients with good performance status and aggressive tumors.

Original languageEnglish (US)
JournalClinical Breast Cancer
Volume8
Issue numberSUPPL. 2
DOIs
StatePublished - Jan 1 2008

Fingerprint

Tubulin
Breast Neoplasms
Taxoids
Microtubules
Biomarkers
Clinical Trials
Cell Shape
Gene Expression Profiling
Transcriptome
Polymerization
Sample Size
Proteomics
Population
Signal Transduction
Neoplasms
Drug Therapy
Survival
Genes
Proteins

Keywords

  • CYP3A4
  • Docetaxel
  • Epothilones
  • Ixabepilone
  • Microtubules

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Predictive markers of tubulin-targeting agents in breast cancer. / Tang, Shou-Ching.

In: Clinical Breast Cancer, Vol. 8, No. SUPPL. 2, 01.01.2008.

Research output: Contribution to journalArticle

@article{c5bdd57f3dc8479e93c906ffe3ec8d04,
title = "Predictive markers of tubulin-targeting agents in breast cancer",
abstract = "Microtubules are formed by an equal amount of α- and β-tubulins through a dynamic process of polymerization and depolymerization that reaches equilibrium. Tubulin-targeting agents affect the microtubule function to disrupt cell shape, microvesicle transportation, and spindle formation. The use of tubulin-targeting agents, especially the newer agents such as taxanes, has significantly increased the response and even survival in patients with many cancers, including breast cancer. However, not all patients respond to these agents. Also, most patients develop recurrent or progressive disease, especially in the metastatic setting. The use of predictive markers of tubulin-targeting agents is therefore needed to increase the therapeutic ratio in the selected patient population. However, many clinical studies have failed to identify reliable and reproducible clinical or biologic markers that serve this purpose. Of the various markers examined, β-tubulin III and its related proteins, such as tau, seem to predict the response to taxanes in preliminary clinical studies. However, most of these studies are limited by many factors such as small sample size, heterogeneous patient population, disease stages, and different methods in marker detection. None of these markers have been validated by large prospective clinical trials. Since tumor cells are driven by many signal transduction pathways, the study of the gene expression signature rather than a single gene is more likely to identify the ultimate predictive markers of response to tubulin-targeting agents. Gene expression profiling and proteomics are in preclinical development and in early clinical trials. They will eventually enable us to offer patients tailored chemotherapy with the tubulin-targeting agents. Before such predictive markers are available, these agents may be considered in patients with good performance status and aggressive tumors.",
keywords = "CYP3A4, Docetaxel, Epothilones, Ixabepilone, Microtubules",
author = "Shou-Ching Tang",
year = "2008",
month = "1",
day = "1",
doi = "10.3816/CBC.2008.s.004",
language = "English (US)",
volume = "8",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Predictive markers of tubulin-targeting agents in breast cancer

AU - Tang, Shou-Ching

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Microtubules are formed by an equal amount of α- and β-tubulins through a dynamic process of polymerization and depolymerization that reaches equilibrium. Tubulin-targeting agents affect the microtubule function to disrupt cell shape, microvesicle transportation, and spindle formation. The use of tubulin-targeting agents, especially the newer agents such as taxanes, has significantly increased the response and even survival in patients with many cancers, including breast cancer. However, not all patients respond to these agents. Also, most patients develop recurrent or progressive disease, especially in the metastatic setting. The use of predictive markers of tubulin-targeting agents is therefore needed to increase the therapeutic ratio in the selected patient population. However, many clinical studies have failed to identify reliable and reproducible clinical or biologic markers that serve this purpose. Of the various markers examined, β-tubulin III and its related proteins, such as tau, seem to predict the response to taxanes in preliminary clinical studies. However, most of these studies are limited by many factors such as small sample size, heterogeneous patient population, disease stages, and different methods in marker detection. None of these markers have been validated by large prospective clinical trials. Since tumor cells are driven by many signal transduction pathways, the study of the gene expression signature rather than a single gene is more likely to identify the ultimate predictive markers of response to tubulin-targeting agents. Gene expression profiling and proteomics are in preclinical development and in early clinical trials. They will eventually enable us to offer patients tailored chemotherapy with the tubulin-targeting agents. Before such predictive markers are available, these agents may be considered in patients with good performance status and aggressive tumors.

AB - Microtubules are formed by an equal amount of α- and β-tubulins through a dynamic process of polymerization and depolymerization that reaches equilibrium. Tubulin-targeting agents affect the microtubule function to disrupt cell shape, microvesicle transportation, and spindle formation. The use of tubulin-targeting agents, especially the newer agents such as taxanes, has significantly increased the response and even survival in patients with many cancers, including breast cancer. However, not all patients respond to these agents. Also, most patients develop recurrent or progressive disease, especially in the metastatic setting. The use of predictive markers of tubulin-targeting agents is therefore needed to increase the therapeutic ratio in the selected patient population. However, many clinical studies have failed to identify reliable and reproducible clinical or biologic markers that serve this purpose. Of the various markers examined, β-tubulin III and its related proteins, such as tau, seem to predict the response to taxanes in preliminary clinical studies. However, most of these studies are limited by many factors such as small sample size, heterogeneous patient population, disease stages, and different methods in marker detection. None of these markers have been validated by large prospective clinical trials. Since tumor cells are driven by many signal transduction pathways, the study of the gene expression signature rather than a single gene is more likely to identify the ultimate predictive markers of response to tubulin-targeting agents. Gene expression profiling and proteomics are in preclinical development and in early clinical trials. They will eventually enable us to offer patients tailored chemotherapy with the tubulin-targeting agents. Before such predictive markers are available, these agents may be considered in patients with good performance status and aggressive tumors.

KW - CYP3A4

KW - Docetaxel

KW - Epothilones

KW - Ixabepilone

KW - Microtubules

UR - http://www.scopus.com/inward/record.url?scp=52449098339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449098339&partnerID=8YFLogxK

U2 - 10.3816/CBC.2008.s.004

DO - 10.3816/CBC.2008.s.004

M3 - Article

C2 - 18637403

AN - SCOPUS:52449098339

VL - 8

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - SUPPL. 2

ER -